-
Professor Jin Jie and Professor Li Jianyong: Pola may become the preferred future treatment of first-line high-risk DLBCL patients
Time of Update: 2023-01-06
Elderly patients with ABC subtype, double blow, double expression, and age > 60 years are difficult to cure from first-line R-CHOP as a high-risk subgroup, and the prognosis is poor, and there is currently no first-line standard treatment for these patients, and there is an urgent need for a better treatment regimen1.
-
Professor Jin Jie and Professor Li Jianyong: Pola may become the preferred future treatment of first-line high-risk DLBCL patients
Time of Update: 2023-01-06
Elderly patients with ABC subtype, double blow, double expression, and age > 60 years are difficult to cure from first-line R-CHOP as a high-risk subgroup, and the prognosis is poor, and there is currently no first-line standard treatment for these patients, and there is an urgent need for a better treatment regimen1.
-
Bispecific antibody partners enhance antitumor activity in mouse lymphoma models| Science Translational Medicine
Time of Update: 2023-01-06
Welcome to pay attention to the official public account of Science, click "Read Original" to visit the original English article, and light up your "like" for medical researchClick on the blue text above to follow usAccording to a new report by Joyce Wei and colleagues, pairing the two bispecific antibodies enhances their antitumor activity against diffuse large B-cell lymphoma (DLBCL) in mouse models.
-
Bispecific antibody partners enhance antitumor activity in mouse lymphoma models| Science Translational Medicine
Time of Update: 2023-01-06
Welcome to pay attention to the official public account of Science, click "Read Original" to visit the original English article, and light up your "like" for medical researchClick on the blue text above to follow usAccording to a new report by Joyce Wei and colleagues, pairing the two bispecific antibodies enhances their antitumor activity against diffuse large B-cell lymphoma (DLBCL) in mouse models.
-
Micro-classroom No. 16 Professor Ma Yanping: Discussion on maintenance therapy suitable for transplanted NDMM patients
Time of Update: 2023-01-06
Autologous hematopoietic stem cell transplantation (ASCT) remains the standard of care for patients with multiple myeloma (TE NDMM) who are candidates for transplantation. In the era of new drugs, sma
-
The Phase 1 clinical trial of ET-01, a gene-edited hematopoietic stem cell candidate for transfusion-dependent β thalassaemia, completed the last patient transfusion
Time of Update: 2023-01-06
On November 18, 2022, Boyaa Ginet announced that its multicenter Phase 1 clinical trial of ET-01, a gene-edited hematopoietic stem cell candidate for transfusion-dependent β thalassemia, has completed the last patient infusion.
-
The Phase 1 clinical trial of ET-01, a gene-edited hematopoietic stem cell candidate for transfusion-dependent β thalassaemia, completed the last patient transfusion
Time of Update: 2023-01-06
On November 18, 2022, Boyaa Ginet announced that its multicenter Phase 1 clinical trial of ET-01, a gene-edited hematopoietic stem cell candidate for transfusion-dependent β thalassemia, has completed the last patient infusion.
-
Together with the joint efforts, UCLI-CDE special session helps innovative drugs to reach the peak of the 7th International Summit Forum on Anti-leukemia and Lymphoma
Time of Update: 2023-01-06
Thinking, communicating, summarizing, and seeking development are the driving forces for the development of medicine, and they are also the habits that doctors in the field of blood have adhered to fo
-
Together with the joint efforts, UCLI-CDE special session helps innovative drugs to reach the peak of the 7th International Summit Forum on Anti-leukemia and Lymphoma
Time of Update: 2023-01-06
Thinking, communicating, summarizing, and seeking development are the driving forces for the development of medicine, and they are also the habits that doctors in the field of blood have adhered to fo
-
Professor Wang Jianxiang: Cohesive force, source of the future - the innovation road of Hergilensa cell injection The 7th International Summit Forum on Anti-leukemia and Lymphoma
Time of Update: 2023-01-06
Figure 6 Hergilencel clinical development planThird, the preliminary data of the Hergilencel clinical studyAbout 50%-60% of adult ALL patients will relapse or refractory to treatment, the prognosis of this part of patients is very poor, although new drugs have been approved for marketing in recent years, but the prognosis improvement is not significant, the overall survival is not significantly improved, only 4~7.
-
Professor Fu Rong: Innovative drugs drive the development of rare disease diagnosis and treatment, and the dilemma of PNH treatment in China is expected to be broken
Time of Update: 2023-01-06
In order to help promote the construction of "Healthy China" and promote the development of rare disease diagnosis and treatment in China, the 2022 China Rare Disease Conference was successfully held
-
Professor Fu Rong: Innovative drugs drive the development of rare disease diagnosis and treatment, and the dilemma of PNH treatment in China is expected to be broken
Time of Update: 2023-01-06
In order to help promote the construction of "Healthy China" and promote the development of rare disease diagnosis and treatment in China, the 2022 China Rare Disease Conference was successfully held
-
Professor Shen Zhixiang: Changes in the field of hematological oncology and suggestions for young doctors The 7th International Summit Forum on Anti-Leukemia and Lymphoma
Time of Update: 2023-01-06
In recent years, with the development of overall science, the field of hematological oncology has undergone earth-shaking changes, and the remission and prognosis of hematological cancer patients have
-
Key points for the diagnosis and treatment of gastric mucosa-associated lymphoid tissue lymphoma: 3 minutes speed reading
Time of Update: 2023-01-06
Chinese Journal of Digestion, 2022, 42(5): 289-303The Sixth National Consensus Report on the Treatment of Helicobacter Pylori InfectionFor Hp-positive local stage (Lugano stage I/II) gastric MALT lymphoma, 60%~80% of patients can achieve remission after eradication of Hp. Hp eradication therapy is ineffective for most gastric MALT lymphomas with t(11,18) translocation, which require chemotherapy and/or radiation therapy.
-
Key points for the diagnosis and treatment of gastric mucosa-associated lymphoid tissue lymphoma: 3 minutes speed reading
Time of Update: 2023-01-06
Chinese Journal of Digestion, 2022, 42(5): 289-303The Sixth National Consensus Report on the Treatment of Helicobacter Pylori InfectionFor Hp-positive local stage (Lugano stage I/II) gastric MALT lymphoma, 60%~80% of patients can achieve remission after eradication of Hp. Hp eradication therapy is ineffective for most gastric MALT lymphomas with t(11,18) translocation, which require chemotherapy and/or radiation therapy.
-
The treatment of MM with extramedullary disease gradually improved, and CD38 monoclonal antibody was successfully shortlisted
Time of Update: 2023-01-06
Table 2 RRMM phase II trial results for Dara-DCEP treatment with EMDA study of 24 patients (14 patients, Isa-Pd; 10 cases, Pd) and 19 (12 cases, Isa-Kd; 7 cases, Kd) patients with soft tissue plasmacytoma were analyzed after the fact6, and the prospect of Isatuximab in MM with EMD was also observed 。 The study showed that at a median follow-up of 18.
-
JCO(IF=51) Shanghai Jiao Tong University multi-unit cooperation, Academician Pei Zhengkang's team found that CAR-T therapy is safe and effective in the treatment of relapsed or refractory B acute lymphoblastic leukemia
Time of Update: 2023-01-06
iNatureIt is unclear whether combination therapy with CD19 and CD22 chimeric antigen receptor T cells leads to durable event-free survival in children with refractory disease or high-risk B acute lymp
-
Professor Li Fei: Seliniso rises to the challenge and breaks the dilemma of multiple myeloma recurrence and incurability!
Time of Update: 2023-01-06
The Guidelines for the Diagnosis and Treatment of Multiple Myeloma in China (2022 Revision)5 points out that 3-4 drugs containing proteasome inhibitors, immunomodulators, daratumumab and nuclear output protein inhibitor celinisol can be selected as much as possible, and salvage autologous hematopoietic stem cell transplantation (ASCT) can be performed if possible 。 BOSTON STUDY7 SHOWED THAT THE MEDIAN PFS IN THE CELINISO PLUS BORTEZOMIB AND DEXAMETHASONE (VD) GROUPS WAS SIGNIFICANTLY LONGER THAN IN THE BORTEZOMIB PLUS DEXAMETHASONE (VD) GROUP (PFS: 13.
-
Case evaluation Professor Hou Ming: The combination of two swords and walls has begun to show strength, the blade out of the sheath to accurately block elderly AML, and the treatment of FLT3 mutant AML by geratinib can be expected in the future
Time of Update: 2023-01-06
05×10 9/L, HGB 54g/L, PLT 7×109/L, combined with pulmonary infection, cardiac insufficiency, treated with meropenem, tigecycline, voriconazole, improved, and considered adjusting the 。Myelocytology: CRFlow cytometry: abnormal myeloid cells < 0.
-
The innovative CD20 monoclonal antibody set sail in the wave of standardized treatment of indolent lymphoma
Time of Update: 2023-01-06
▎Professor Zhang Qingyuan:In the clinical treatment of FL, obinutuzumab has a wealth of evidence-based medical evidence, including the GALLIUM study is a global multicenter, randomized controlled phase III study comparing the efficacy of obinutuzumab in combination with chemotherapy (G-chemotherapy group) and rituximab plus chemotherapy regimen (R-chemotherapy group) in induction therapy in patients with treatment-naïve FL 。 Results showed that the G-chemotherapy regimen significantly improved PFS (3-year PFS rate 80.
